Elanco Animal Health Incorporated (ELAN)
$
21.69
-0.21 (-0.97%)
Key metrics
Financial statements
Free cash flow per share
0.7287
Market cap
10.9 Billion
Price to sales ratio
2.3701
Debt to equity
0.5962
Current ratio
2.4007
Income quality
17.4722
Average inventory
1.7 Billion
ROE
0.0055
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Elanco Animal Health Incorporated is an established player in the animal health sector, innovating and developing a diverse array of products designed for both pets and farm animals. The company reported an income before tax of 488,000,000.00 showcasing its pre-tax profitability. The cost of revenue for the company is $2,530,000,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $4,188,000,000.00 reflecting its overall spending. Additionally, Elanco reported selling, general, and administrative expenses of $1,314,000,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is 497,300,000.00 reflecting potential dilution effects. Elanco focuses on pet health with disease prevention products such as parasiticides and vaccines protecting pets from common parasites like worms, fleas, and ticks under renowned brands including Seresto, Advantage, Advantix, and Advocate. It also offers therapeutics for various conditions in canines and felines under the Galliprant and Claro brands. Moreover, the company provides vaccines, antibiotics, and nutritional health products for poultry and aquaculture, alongside essential products for ruminant and swine production under the Rumensin and Baytril brands. Elanco serves a broad customer base, including third-party distributors, veterinarians, and farm animal producers ranging from beef and dairy farmers to those in the pork and poultry sectors. As an organization, Elanco Animal Health operates within the Healthcare sector, driving innovation and growth within the industry. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Investors seeking budget-friendly options may find the stock affordable at $19.20 making it suitable for those who are budget-conscious. Additionally, the stock has a high average trading volume of 5,293,295.00 indicating strong liquidity in the market. With a mid-range market capitalization of $10,776,968,729.00 the company is recognized as a steady performer, showcasing its reliability and consistent contributions to the animal health field.
Is Elanco Animal Health Incorporated (ELAN) a good investment?
Investing in Elanco Animal Health Incorporated (ELAN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Elanco Animal Health Incorporated (ELAN)'s stock forecast?
Analysts predict Elanco Animal Health Incorporated stock to fluctuate between $8.02 (low) and $23.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Elanco Animal Health Incorporated's market capitalization?
As of 2025-12-08, Elanco Animal Health Incorporated's market cap is $10,776,968,729, based on 496,863,473 outstanding shares.
How does Elanco Animal Health Incorporated compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Elanco Animal Health Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Elanco Animal Health Incorporated (ELAN) stock?
To buy Elanco Animal Health Incorporated (ELAN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ELAN. Place an order (Market, Limit, etc.).
What is the best time to invest in Elanco Animal Health Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Elanco Animal Health Incorporated perform in the last earnings report?
Revenue: $4,439,000,000 | EPS: $0.68 | Growth: -127.20%.
Where can I find Elanco Animal Health Incorporated's investor relations reports?
Visit https://www.elanco.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Elanco Animal Health Incorporated?
You can explore historical data from here
What is the all-time high and low for Elanco Animal Health Incorporated stock?
All-time high: $36.50 (2021-08-05) | All-time low: $7.88 (2023-05-31).
What are the key trends affecting Elanco Animal Health Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to
seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Presents at Evercore 8th Annual Healthcare Conference Transcript
prnewswire.com
/PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ and NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to
prnewswire.com
MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.
benzinga.com
As the pet care industry experiences rapid growth, pharmaceutical companies are increasingly focusing on developing innovative treatments for companion animals.
youtube.com
Jeff Simmons, Elanco Animal Health CEO, joins 'The Exchange' to discuss what's driving the company's earnings results, where the company's is devoting the most resources and much more.
seekingalpha.com
Elanco Animal Health Incorporated ( ELAN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tiffany Kanaga Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Linda Bolduc - Morgan Stanley, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Navann Ty Dietschi - BNP Paribas, Research Division Andrew Dusing - Cleveland Research Company LLC Presentation Operator Ladies and gentlemen, thank you for standing by.
zacks.com
The headline numbers for Elanco Animal Health (ELAN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.13 per share a year ago.
See all news
